Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Product Use Citation(85)

Customer Product Validation(11)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KBNUTWeGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLtPZNtUUN3ME2wMlA2PCEQvF2=Ml[1NVY2OTZ2N{O=
NIH3T3MVnGeY5kfGmxbjDBd5NigQ>?NXLOTpRwOC5{IN88US=>M2SzO|IhcA>?MUHEUXNQMoLkTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txOMl[5NVY1QDB{OES=
COS7NYPRRlE1TnWwY4Tpc44hSXO|YYm=MnvDPVYh|ryPMljGTY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>MorUNVcyPzh5MkK=
A549MnH1R5l1d3SxeHnjJGF{e2G7NXXKb3VLQTZiaB?=MnTRSG1UVw>?M17ZZ2lEPTB;MUOuOVkh|ryPNV\0[mkxOTh|MUO4NFc>
K562NU\2SJk5S3m2b4TvfIlkKEG|c3H5MkfVPVYhcA>?M2\HcWROW09?NFTzWXpKSzVyPUmuN|Yh|ryPNIrZSG4yQDNzM{iwOy=>
MDA-MB-231NFHCN25EgXSxdH;4bYMhSXO|YYm=MojEPVYhcA>?MWnEUXNQNWXNTGlYUUN3ME2zOk43OSEQvF2=NGTHN5MyQDNzM{iwOy=>
MOLT4MXnDfZRwfG:6aXOgRZN{[Xl?M2Sxc|k3KGh?MnnBSG1UVw>?NFnMUGFKSzVyPUG1MlAzKM7:TR?=NEDSZYkyQDNzM{iwOy=>
MCF7M1W2fWN6fG:2b4jpZ{BCe3OjeR?=MlKyOVAh|ryPM3n4NFczKGh?NYLCdFlyUUN3ME2xNk4xPSEQvF2=MmjhNVg4PzF6MUm=
BT474NVrEW2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzG[I84OiCqMXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txOMVOxPVAzQDR{NB?=
HN5MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nnXFczKGh?Mn\RRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEWFNUCgc4YhOC5yMTFOwG0>NGHZbFAyQTB{OESyOC=>
BA/F3M1\FcmN6fG:2b4jpZ{BCe3OjeR?=MlXpO|IhcA>?M{XoPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRid3n0bEBKSzVyIH;mJFAvODFyODFOwG0>MXuxPVI{QTJ{OR?=
NIH3T3NUjUUGN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7CZ5A4OiCqM3zQXmdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txOM2qwNlE6PjZ3M{e3
MCF7 MXM2LKb2Z2dmO2aX;uJGF{e2G7M2fjWFMxKG2rbh?=MnTRTY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?NX75UWpGOTl7M{K5OlA>
A431NX;xPWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nNUlExKM7:TR?=MlnQO|IhcA>?NXS4dWNRT0l3ME2wMlUyPCEQvF2=NX:2S3d5OTl7Nkm0OlU>
A431NGn0UGNMcW6jc3WgRZN{[Xl?M3\FfVAvOSEQvF2=MlPINUBpM3TZVmlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>NGDDc5MyQTl4OUS2OS=>
A431M2HrVmtqdmG|ZTDBd5NigQ>?NULUemZbOTByIN88US=>MVWxNEBucW5?NHTicXJRem:ub37n[YQhcW6qaXLpeI9zgSCjY4Tpeol1gSCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?NX;jcXNiOTl7Nkm0OlU>
Sf9MV7LbY5ie2ViQYPzZZk>MkfXNVAhdWmwM4nLfWROW09?NFXZWZFKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszNNH7jcHozODB3NkSyOS=>
NCI-H1975NYnmXoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTxd|U2KM7:TR?=MkTpO|IhcA>?MXPJR|UxRThwMk[g{txOM3TvRlIxOTVzNkew
NCI-H1975MoHiT4lv[XOnIFHzd4F6NFywcogyOCEQvF2=NYfOPHNKUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?NYj0RVVxOjBzNUG2O|A>
NCI-H1975MWTGeY5kfGmxbjDBd5NigQ>?M1\sfFExKM7:TR?=MnrNTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9vMn3INlAyPTF4N{C=
NCI-H1975NYPue2NKTnWwY4Tpc44hSXO|YYm=MnvhOUDPxE1?NHS2eFA1QCCqMl7jTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UuOw>?NGn4bmwzODF3MU[3NC=>
A375NWezbG9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Pvc|Q5KGh?NYLkdHNxUUN3ME2yNE42PSEQvF2=NX7UUGxGOjB|MES1N|c>
SMMC7721NWTSO|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVr1U3JiPDhiaB?=NH7ve3FKSzVyPUOzMlEzKM7:TR?=MUKyNFMxPDV|Nx?=
DU145M3\aZmN6fG:2b4jpZ{BCe3OjeR?=NVrKcFdSPSCmMmfaSG1UVw>?NEjycnVKSzVyPUSyMlE4KM7:TR?=NFTtN5MzODR4NkW1OS=>
MIAPaCa2NI\zRpdEgXSxdH;4bYMhSXO|YYm=NGDzW3I2KGR?MkDNSG1UVw>?NUDhTGpzUUN3ME21NE43OiEQvF2=MXGyNFQ3PjV3NR?=
PANC1NXvCWIlZS3m2b4TvfIlkKEG|c3H5NFzhbZA2KGR?NIHsUWdFVVORMUnJR|UxRTRyLkSyJO69VQ>?NHvselQzODR4NkW1OS=>
PC9M3O4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFXHSnIu\GWoaXPp[Y51KGi3bXHuJHBEQSClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wNVch|ryPNGDwS3czOTJyOEiwNi=>
PC9MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfyc5d1cC2{ZYPpd5RidnRiaIXtZY4hWEN7IHPlcIx{KGW6cILld5NqdmdiRVfGVkBGPzR4X1G3OVAwXDd7MF2gcZV1[W62IIfpeIghTUN3MDDv[kA4KM7:TR?=NGnDelUzOTJyOEiwNi=>
PC3MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYWxNEDPxE1?NUn1[2wzPzJiaB?=NV3nU|RwTE2VTx?=NV\0PJNGUUN3ME23MlQh|ryPMXWyNVM2OzV2Nh?=
MDA-MB-468NFXXbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPWNVAxKM7:TR?=MW[0PEBpNF3GV4FFVVORMXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=MXiyNVQzQTZ|Mh?=
Plasmodium falciparumMkW1dWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?MmfUNlE5OTdyNEW=
NCI-H1993M4LpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXS3NkBpM1TZNWROW09?NIn6R5hKSzVyPUCuNUDPxE1?MYGyNVkyPjR|Mx?=
NCI-H292NH;4W3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUC3NkBpNYLsOI5OTE2VTx?=NGPhUlhKSzVyPUCuNFIh|ryPNXvIcpNMOjF7MU[0N|M>
A431NEnzN3NMcW6jc3WgRZN{[Xl?NEX2TJkzKGh?Ml3GSG1UVw>?MmTNTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCDNEOxJJdqfGhiSVO1NEBw\iByLkCwNUDPxE1?MlL5NlIyODFzM{K=
MCF7NXnDNGRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofwNVAxyqEQvHevcWw>Ml3KOFghcA>?MY\EUXNQNXvUbpdiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txONH7iO4MzOjFzOUGzNC=>
BT474NGGxc29EgXSxdH;4bYMhSXO|YYm=MVyxNEDPxE1?MmXEOFghcA>?MlLpR5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCEVES3OEBk\Wyucx?=MnLlNlIyOzh|MEi=
MCF7MUjDfZRwfG:6aXOgRZN{[Xl?MmfQNVAh|ryPNVvVNXFKPDhiaB?=M3LaWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=NUHUOpFxOjJzM{izNFg>
HCC827MX;LbY5ie2ViQYPzZZk>NU\2VZN7OC5zMkWg{txONXHHWHlLOjRiaB?=MoLrSG1UVw>?M{nkTGlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9vNET0OFAzOjN|OUO0Ni=>
HCC827MlfLT4lv[XOnIFHzd4F6MXuwMlEzPSEQvF2=MV:yOEBpMX;EUXNQMWPJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?MWOyNlM{QTN2Mh?=
HCC827NIPNSYdMcW6jc3WgRZN{[Xl?MkTLNE4yOjVizszNNYrI[2pMOjRiaB?=M3S0WGROW09?MoH0TY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?M3;3SlIzOzN7M{Sy
A431M2jPdmtqdmG|ZTDBd5NigQ>?NVS2W|JQOTByIN88US=>Mn\BN|AhdWmwMlzLTY5pcWKrdHnvckBw\iCHR1\SJIRmemm4ZXSg[pJwdSCqdX3hckBCPDNzIHPlcIwhdWWvYoLhcoUh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7LVfseU1VgXJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxMlA5KM7:TR?=MUiyNlY6QDd6Mh?=
H460NHiyeppEgXSxdH;4bYMhSXO|YYm=MVi3NkBpMof3TWM2OD13LkW5JO69VQ>?Mnf1NlI4Ojd2NEm=
HT-29MX7DfZRwfG:6aXOgRZN{[Xl?MUG3NkBpM4fXNmlEPTB;Mz6zOkDPxE1?NWjTb5FSOjJ5Mke0OFk>
SGC7901M33QbmN6fG:2b4jpZ{BCe3OjeR?=NWTqW5p6PzJiaB?=NGTEcG1KSzVyPUGwMlI3KM7:TR?=M1nlcVIzPzJ5NES5
A498NVTaUHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zJdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=M{WwbVIzQDF6OES4
Calu3NXXlbXZxS3m2b4TvfIlkKEG|c3H5Mlm4NVAh|rypL33MMXq3NkBpNHjlS|JKSzVyPUGuOkDPxE1?Mlz5NlMyOTZzNki=
FADUNV\EZVl7S3m2b4TvfIlkKEG|c3H5Mk\LNVAh|rypL33MM{LEfFczKGh?NUPQbpVxUUN3ME2wMlA2KM7:TR?=M1u2PFI{OTF4MU[4
HCC827M4n3XWN6fG:2b4jpZ{BCe3OjeR?=MXGxNEDPxGdxbVy=NHS5TYs4OiCqNGTNUnZKSzVyPUCuNFAyPSEQvF2=NUDrSFhEOjNzMU[xOlg>
PC9M1HwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjuWZM1OTBizsznM41NMlXuO|IhcA>?NF:4dHpKSzVyPUCuNFAyPCEQvF2=M33jWFI{OTF4MU[4
Sf9NHu2OXRMcW6jc3WgRZN{[Xl?MXWxJIg>NXSxfVZkTE2VTx?=Mm\rTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvdHHn[4VlKEWJRmKgUFg{PFJibYX0ZY51KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4xOTVizszNMo\HNlM3OTF4OUG=
16HBE14o-NX\ndFlqS3m2b4TvfIlkKEG|c3H5NVWxcINbOTBizszNNYXBRZljPzJiaB?=M2G5d2ROW09?MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>MV2yN|Y3QDR2MR?=
NCI-H1975M4LZNWN6fG:2b4jpZ{BCe3OjeR?=M13kPVExKM7:TR?=NF\RTlg4OiCqNHLCW5RFVVORNUfQ[m1LS3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch|ryPMmW1NlM3Pjh2NEG=
16HBEMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXmzdVNYPzJiaB?=MXjEUXNQMXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKDF4SFLFJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJid3n0bEBKSzVyIH;mJFEvPjBzIN88US=>NEHGTYIzOzd7MkOxPC=>
16HBENEiyepFHfW6ldHnvckBCe3OjeR?=NFn4[WEyODBizszNM4GxRVE2OCCvaX6=M3TCZWROW09?MnvLTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>M3K5[|I{Pzl{M{G4
A549NHjKd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGL2O3M4OiCqM1HVdWROW09?NYPTb2U5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhTUeIUj;rMXJieyCmZYDlcoRmdnRiaIXtZY4hSTV2OTDj[YxteyC5aYToJGlEPTBib3[gOE43OjZizszNMWiyN|c6OjNzOB?=
SH-SY5YMYTDfZRwfG:6aXOgRZN{[Xl?MofNO|IhcA>?NX7kfoNnUUN3ME2xPE4zOSEQvF2=M17GUlI{QDdzOUC5
LoVoMmjpT4lv[XOnIFHzd4F6NIXNc3ozKCCqMV;EUXNQNES4c|JKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC2NkDPxE1?NH3jVY4zOzl|MEm5OC=>
PC9MofYT4lv[XOnIFHzd4F6NFS5UG0zKGh?MY\EUXNQM{nvdmlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?MU[yN|k{ODl7NB?=
HCC827M37xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzkfIREPzJiaB?=NF3Id4xKSzVyPUCuNFEzKM7:TR?=M1HtbFI{QTd|MU[4
A549NEjOZYVMcW6jc3WgRZN{[Xl?NVjwU4FkOSEQvF2=MWOxJIg>MUPEUXNQMXzJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|k6KM7:TR?=M4\YcFI{QTh6M{W0
A549NIryc3hHfW6ldHnvckBCe3OjeR?=NF3TZXcyKM7:TR?=MkfiNUBpNHjGd|VFVVORMnzjR4VtdHWuYYKgeZB1[WunNGf0bZEzOzl6OEO1OC=>
HCC827NYDJO2E3U2mwYYPlJGF{e2G7M13SdVAvPSEQvF2=MkDINkBpNVe1NmJ1TE2VTx?=NWryNFRtUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=MYCyN|k6OzN{OB?=
HCC827MmnFSpVv[3Srb36gRZN{[Xl?MmPFNE42KM7:TR?=M37CUlIhcA>?NFjxfIZFVVORNWr0WYlrUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=NEe2XlUzOzl7M{OyPC=>
HCC827M1rQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XJb|ExKM7:TR?=MoPlO|IhcA>?NVjHWYt1TE2VTx?=M{jmVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZNmdnOrdHn2[UBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO|UxKGSnbHX0bY9vKHerdHigTWM2OCCxZjCwMlAxPThzIN88US=>MXyyOFA2OzZ5NB?=
A431MmTnT4lv[XOnIFHzd4F6MlvBNVAxKM7:TR?=NYDl[Y5LOzBibXnuM3vxVmlvcGmkaYTpc44hd2ZiRVfGVkBqdiC|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txONHjBT3IzPDB7NESzNi=>
BCRP-MDCK2NUX3VpprTnWwY4Tpc44hSXO|YYm=MnmxNU45KM7:TR?=Mn75O|IhcA>?MV;EUXNQMWHJcoNz\WG|ZTDv[kBxdGG|bXGgcYVu[nKjbnWg[ZhxemW|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>M4PlNFI1OTh2MkGz
BCRP-MDCK2NUjKOIhsTnWwY4Tpc44hSXO|YYm=M{\FWVEvQCEQvF2=MVK3NkBpNInGSpZFVVORNEXxOlVT\WS3Y4Tpc44hd2ZicHzhd41iKG2nbXLyZY5mKGW6cILld5Nqd25ib3[gRmNTWCCneIDy[ZN{cW6pIILldI9zfGW{IHflcoUhT0[SNGLibJozPDF6NEKxNy=>
MDCKM1\OOWN6fG:2b4jpZ{BCe3OjeR?=NFPVV4M4OiCqMn\mSG1UVw>?NGjIXIdIUTVyPUGuOFUh|ryPMUGyOFE5PDJzMx?=
MDCK2MVrGeY5kfGmxbjDBd5NigQ>?M4LGd|EvQCEQvF2=MYC3NkBpNXvrNmpCTE2VTx?=Ml\3TY5pcWKrdHnvckBw\iCqdX3hckBDS1KSIHX4dJJme3OnZDDhd5Nme3OnZDDhd{BJd2WlaIP0JFM{OzR{IHHjZ5VufWyjdHnvckB4cXSqIFnDOVAhd2ZiMz6xPUDPxE1?NHPHZXMzPDF6NEKxNy=>
A431M{\Wb2N6fG:2b4jpZ{BCe3OjeR?=MlXiO|IhcA>?MkLlSG1UVw>?NUTwSGV7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIECuOVUh|ryPNVrDWpROOjR2MUGxNlM>
Calu3MXjDfZRwfG:6aXOgRZN{[Xl?M4GwWVczKGh?MVfEUXNQMnyxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJJdqfGhiSVO1NEBw\iByLkm5JO69VQ>?M4i3WVI1PDFzMUKz
KBNYDzTZNnU2mwYYPlJGF{e2G7M2PhUFExKM7:TR?=MVWxJIg>NHL1bmRFVVORM3rQOWlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=MWSyOFQyOTF{Mx?=
BEAS2BNITHRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nkOlUxKM7:TR?=M1nvOVczKGh?MVrEUXNQNUW3Vlk{UUN3ME2xN{46PCEQvF2=NYLVfmc4OjR4MEe1PVE>
NCI-H1975NYPnNpFDTnWwY4Tpc44hSXO|YYm=MnzjNVAxKM7:TR?=M3Loc|E2OCCvaX6=NF3UOGRFVVORMkX1TY5lfWO2aX;uJI9nKE6RIIDyc4R2[3Srb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfA>?NY\6UoxwOjR4MEe1PVE>
HelaNETIOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUKyOEBpNGj2VmZFVVORM4TXW2lEPTB;Mj62O{DPxE1?MUiyOFc{OTJ6MR?=
HepG2M1HEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rtelI1KGh?M4L0OGROW09?MojDTWM2OD14LkSyJO69VQ>?M3XBbFI1PzNzMkix
Sf9MoHyT4lv[XOnIFHzd4F6NYHiRmdxOTBibXnuMkHYSG1UVw>?NEH4fppKdmirYnn0bY9vKG:oIHH1eI9xcG:|cHjvdplt[XSrb36gc4YhemWlb33ibY5idnRiaHnzMZRi\2enZDDFS2ZTKCijbXnuc{Bi[2mmIE[0OU0yOTh4KTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEKg{txONIHDXpczPDd|MUK4NS=>
SW620NFPINVZEgXSxdH;4bYMhSXO|YYm=MnTOOFghcA>?M4XodGROW09?MXvJR|UxRTJ6LkKg{txONUTaU4t2OjR7MEC1PVQ>
HCC827M4e3PGZ2dmO2aX;uJGF{e2G7MUOwMlUh|ryPMUSyJIg>NYrQWVU1TE2VTx?=NVXyOZJn\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHLWEBxcG:|cHjvdplt[XSrb36=MXSyN|k6OzN{OB?=
HCC827NYr6[49DTnWwY4Tpc44hSXO|YYm=NFflfG0xNjVizszNM4\sV|IhcA>?MkH4SG1UVw>?NY\3WIhF\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIC0OE81OiCyaH;zdIhwenmuYYTpc44>MmPvNlM6QTN|Mki=
HCC827NH3FTIFEgXSxdH;4bYMhSXO|YYm=NYXQTXh7OC53IN88US=>NYHVeWNlPzJiaB?=NYLVNIY3TE2VTx?=M2LheohieyCwbzDjfZRwfG:6aXPpeJk>M1\tVlI{QTl|M{K4
NCI-H1975NEnaXldHfW6ldHnvckBCe3OjeR?=NHzIcnAyOCEQvF2=NYXKT3BpQCCqNGLW[VBFVVORNVvFd2xv\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=M3PCdlI{OTF4MU[4
A431M3HGe2tqdmG|ZTDBd5NigQ>?MmnUNUDPxE1?Mn;wNUBpNGK3VJhFVVORNW\i[VRicGG|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=NVr3O2hqOjR7MEC1PVQ>
LNCaPMV\GeY5kfGmxbjDBd5NigQ>?Ml\JNVAh|ryPM4e5eFJpKG:{IESgbC=>NILGbotFVVORM2LGc4Rw\XNibn;0JIlvcGmkaYSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCrbX31co9xfXKrZnnl[EBndGGpLYTh[4dm\CCEbYigZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcOzKSXVHUVC=>NWLMXpZjOTh4NkezNVI>
H1975MUHLbY5ie2ViQYPzZZk>MlfMNUDPxE1?NXn1ZW5zOjRiaB?=MnjkSG1UVw>?M4\iNYRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51M1rwfVI1PjB5NUmx
H1975MUjGeY5kfGmxbjDBd5NigQ>?M{Dne|Eh|ryPNX7mWGs2OjRiaB?=NVza[4U{TE2VTx?=MVLkc4V{KG6xdDDpcohq[mm2IFXST{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0>NHS4bXozPDZyN{W5NS=>
HCC827NG\ad4lMcW6jc3WgRZN{[Xl?NFvBb2ExNjFzIN88US=>M{TZS|EhcA>?MkDGSG1UVw>?M3vBVYhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG|c3Xzd4VlKGG|IILlZ493\XK7IH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=NEjUV28zPDF{NEi5PC=>
H1975MoflT4lv[XOnIFHzd4F6MYiwMlM{KM7:TR?=MXmyJIg>MWnEUXNQMnjn[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44>MoS2NlQyOjR6OUi=
H1975NGf1NGRMcW6jc3WgRZN{[Xl?M1POPFAvOzNizszNMoPHNkBpNIrkd2hFVVORNYfIWZJ4\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?MmjXNlQyOjR6OUi=
H1975NFTVTG1McW6jc3WgRZN{[Xl?MlvENE4{OyEQvF2=M2G3[FIhcA>?M3TNdGROW09?MXfkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:|cHjvdplt[XSrb36=NV\zN25DOjRzMkS4PVg>
H1975MYjLbY5ie2ViQYPzZZk>NIPvd5AxNjF{NTFOwG0>Ml;ZNlQhcA>?NWXYXHZETE2VTx?=NH7JPJhld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?NEP1[mkzOjN|OUO0Ni=>
H1975M4\zc2tqdmG|ZTDBd5NigQ>?M13SNVAvPSEQvF2=MonNNlQhcA>?M{HmPWROW09?M1;mXoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=MnHrNlI{Ozl|NEK=
H1975MVrLbY5ie2ViQYPzZZk>M4H3N|AvPSEQvF2=NEK1XogzPCCqNHXlXVdFVVORMXvkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?NWTvXGlPOjJ|M{mzOFI>
MIAPaCa2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnLd5czNjVizszNM37DTlczKGh?MmrvSG1UVw>?MlOwbIF{KG6xIHfyc5d1cCCrbnjpZol1cW:wNX;B[Yl[OjB2Nk[1OVU>
MIAPaCa2MVrDfZRwfG:6aXOgRZN{[Xl?NHTkeGMyKM7:TR?=MUWxNEBlMmnmSG1UVw>?NHq0Ooxp[XNibn:gZ5l1d3SxeHnjbZR6KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44>M3rU[lIxPDZ4NUW1
MIAPaCa2MkXORZBweHSxc3nzJGF{e2G7NFPofYsyOCEQvF2=NUC3blFsOjSqIH;yJFQ5KGh?M1jqVWROW09?M3TvNoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO=NWX6WIVtOjB2Nk[1OVU>
MIAPaCa2M4e0b2Fxd3C2b4Ppd{BCe3OjeR?=MYiyNEDPxE1?NIXHbVIzPCCqM2fSOWROW09?M4PtW4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMh[2G|cHHz[UA{KGGldHn2ZZRqd25?NYrxToNVOjB2Nk[1OVU>
EoL-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTVwMUegcm0>M13lfXNCVkeHUh?=
NCI-H720M33MRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTJ4LkmyJI5OMXvTRW5ITVJ?
NCI-SNU-5NWHtW4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O5UmlEPTB;MkiuNVkhdk1?M2HTe3NCVkeHUh?=
EW-3NUPzVI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTSTWM2OD12Nj6wOEBvVQ>?M3TSRXNCVkeHUh?=
HCC2218MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTVyLkW5JI5ONU\iSIpOW0GQR1XS
HuO-3N1MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3P3cWlEPTB;NU[uNFkhdk1?NHrBd3lUSU6JRWK=
DBNILOXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTZyLkm2JI5ONEmxVYVUSU6JRWK=
HSC-4NF3oTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHnWpJKSzVyPU[xMlU{KG6PNEDVPG1USU6JRWK=
DOKM1z1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LMSmlEPTB;OUOuOlIhdk1?NF33PFBUSU6JRWK=
H9NFf1TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjyTWM2OD1zM{euNkBvVQ>?MnT3V2FPT0WU
NCI-H292MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfwTWM2OD1zNkKuOlYhdk1?M2e0UHNCVkeHUh?=
HSC-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHu3d4dKSzVyPUG2OU42PyCwTR?=NG\i[Y9USU6JRWK=
LU-65MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojoTWM2OD1zNk[uOlEhdk1?MUnTRW5ITVJ?
BV-173NHjpXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF6Nj61OUBvVQ>?NUHLVXFWW0GQR1XS
LB2241-RCCMl7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[zc4ZiUUN3ME2xPVQvQTNibl2=NUXyNppHW0GQR1XS
KG-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfnU45jUUN3ME2yNFQvOzRibl2=MVvTRW5ITVJ?
CHL-1NEO4VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;HRVdKSzVyPUKwPE42OSCwTR?=NWfyNoQxW0GQR1XS
KYSE-140MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfhTWM2OD1{MEmuPVYhdk1?NED4OnBUSU6JRWK=
DU-145NGj5UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3JTWM2OD1{MUmuNFQhdk1?MYrTRW5ITVJ?
EW-13M4fvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUS0fIVmUUN3ME2yNlUvOSCwTR?=MlvLV2FPT0WU
KYSE-450M3zvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vQSGlEPTB;MkS3MlkzKG6PNV76NI9GW0GQR1XS
CAL-72NGDsOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoO5TWM2OD1{NkiuO|Mhdk1?Ml[wV2FPT0WU
MEG-01MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvlPI9lUUN3ME2yO|YvPzZibl2=M3LRSnNCVkeHUh?=
HCE-TMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn34TWM2OD1{N{muO|khdk1?MlzvV2FPT0WU
NCI-SNU-1MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\kR5ZKSzVyPUK4N{4{OiCwTR?=NUC1eWhkW0GQR1XS
CAL-27MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPqTWM2OD1{OEmuNFghdk1?MnHjV2FPT0WU
BALL-1NXvEUYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJ7Nz60NkBvVQ>?NGLhcIFUSU6JRWK=
SBC-1NEGxWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXPTWM2OD1|MEeuO|khdk1?NEjvU3VUSU6JRWK=
CAL-54MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjFOmdKSzVyPUOxNU4zOyCwTR?=MVLTRW5ITVJ?
TI-73NF3VT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:xdpVmUUN3ME2zNVIvPzVibl2=MYjTRW5ITVJ?
P12-ICHIKAWANUfze484T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXm4eVZsUUN3ME2zNlgvODZibl2=NGHQSppUSU6JRWK=
ACHNNF6wVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHUdmNKSzVyPUOzNU41KG6PNELpb|JUSU6JRWK=
PC-14MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\X[GlEPTB;M{OzMlQyKG6PMkXRV2FPT0WU
HCC1806MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjHWlcyUUN3ME2zN|cvPTFibl2=NIjjXY5USU6JRWK=
SK-MEL-24NXjNd|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXLTWM2OD1|M{euPFchdk1?Mn[1V2FPT0WU
A4-FukM{i4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnpNHdTUUN3ME2zOVAvODJibl2=M3TReXNCVkeHUh?=
ECC10M37L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXTTWM2OD1|NUKuPVYhdk1?MUHTRW5ITVJ?
KASUMI-1Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PkdWlEPTB;M{[2Mlc{KG6PNWTsRWJFW0GQR1XS
CAL-33MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jobmlEPTB;M{ewMlkhdk1?M3XoZnNCVkeHUh?=
MDA-MB-175-VIIM2DUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3z6S2lEPTB;M{e4Mlg5KG6PNWr5ZVVPW0GQR1XS
NUGC-3Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvsdZR[UUN3ME20NFEvQDFibl2=NIftXGFUSU6JRWK=
KY821M3XzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3qz[WlEPTB;NEC4MlU4KG6PMVPTRW5ITVJ?
CTB-1M1\N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTR{ND60JI5OMXXTRW5ITVJ?
DoTc2-4510M1jLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDuWZdKSzVyPUS0Nk4yOiCwTR?=MXTTRW5ITVJ?
EFO-27NVexdJZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXz2WmNwUUN3ME20OVQvPzRibl2=MkXuV2FPT0WU
BPH-1M3n5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnGTWM2OD12OUGuNVYhdk1?MXfTRW5ITVJ?
KYSE-270NYD4PVRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEW2cWlKSzVyPUS5PE43PSCwTR?=NVLzbI9LW0GQR1XS
HO-1-N-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTVyOT6yOUBvVQ>?MXLTRW5ITVJ?
SK-MEL-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHZXXJDUUN3ME21NVAvQTlibl2=MYrTRW5ITVJ?
MOLT-13NIjlUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnwSXFKSzVyPUWxOE45OiCwTR?=NF;WRmFUSU6JRWK=
TK10NInSb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfJTWM2OD13MUWuNVEhdk1?NWjrZXcyW0GQR1XS
HNNWXoWFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYn6fINkUUN3ME21NVcvOzhibl2=NWPmV5NUW0GQR1XS
SCC-15NVzGPJJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7UbnFPUUN3ME21NlUvPjhibl2=NFvnNlZUSU6JRWK=
NCI-H358M{frOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\KTWM2OD13MkeuOlYhdk1?NHu5W2ZUSU6JRWK=
KYSE-180NFrRc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXoTWM2OD13M{CuOlIhdk1?Mn7CV2FPT0WU
NCI-H82M2LQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTV2MD61JI5ONWjkNpR6W0GQR1XS
NB7NUHaTIFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TDRmlEPTB;NUS2MlMzKG6PM37BVXNCVkeHUh?=
DSH1M4nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLyTWM2OD13Nk[uPFghdk1?NFHPZ4FUSU6JRWK=
RS4-11M3XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjxfWdIUUN3ME21OlgvPTlibl2=NIrKVJNUSU6JRWK=
CANM3jIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDXVZVrUUN3ME21PFAvPzZibl2=MXLTRW5ITVJ?
Ca9-22NWfvNIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjYdWhKSzVyPUW4PE43PCCwTR?=NIP4cpFUSU6JRWK=
CAL-39MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTV7Nj6zJI5ONX3tWJN{W0GQR1XS
NCI-H1623MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrifWxKSzVyPUW5PU4{PiCwTR?=M2KwSnNCVkeHUh?=
FADUMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1THZmlEPTB;NkC0MlY6KG6PMl3OV2FPT0WU
NB69NIDJV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrkWFlKSzVyPU[xOE4{PSCwTR?=M{n4dXNCVkeHUh?=
Ramos-2G6-4C10NGC4TW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PDdWlEPTB;NkKxMlQ3KG6PMUnTRW5ITVJ?
LB1047-RCCM1LzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjSdWR[UUN3ME22NlUvOjlibl2=NHzncpdUSU6JRWK=
MV-4-11MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LKdGlEPTB;NkK3Mlchdk1?NHPLNHlUSU6JRWK=
DBTRG-05MGNETOW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXaTWM2OD14M{KuNlghdk1?NUXHdFdYW0GQR1XS
ME-180NX[3WFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjycHRKSzVyPU[zNk46KG6PMl\WV2FPT0WU
NBsusSRNHraVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzhXnRKSzVyPU[0Ok42OiCwTR?=M1OwWXNCVkeHUh?=
COR-L105NYfuZXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTOVJkzUUN3ME22OlIvPTNibl2=MW\TRW5ITVJ?
ETK-1M1yxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjjZol5UUN3ME22OlIvPTlibl2=NFLUZ4dUSU6JRWK=
L-363NI\UfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHGTWM2OD14N{GuPVQhdk1?MYTTRW5ITVJ?
LU-134-ANYrPOmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTdzOT6wPUBvVQ>?MXfTRW5ITVJ?
NCI-H1770NXXFOnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrnOpdKSzVyPUeyNk41KG6PMVXTRW5ITVJ?
HAL-01Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7zfFRKSzVyPUezOE44OSCwTR?=MVfTRW5ITVJ?
COLO-684MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DWd2lEPTB;N{WzMlAyKG6PM4T1RnNCVkeHUh?=
TE-6MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTd4ND6zNUBvVQ>?M1nX[3NCVkeHUh?=
A431NGm2R2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTd6MD6wOEBvVQ>?MVrTRW5ITVJ?
LU-135M3vBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTd6Mz6wN{BvVQ>?NEOyZWpUSU6JRWK=
EC-GI-10MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTd6OD61NkBvVQ>?NHS3VnRUSU6JRWK=
TE-12MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTh{MT6xNUBvVQ>?MYHTRW5ITVJ?
LoVoMmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTh3OT6wOkBvVQ>?NFTodmZUSU6JRWK=
23132-87MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrkTWM2OD16NkSuNlghdk1?MVPTRW5ITVJ?
AU565MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTh4OT62JI5ONGfWWHZUSU6JRWK=
DELMmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV2zSpRIUUN3ME24O|cvPjVibl2=M1i4WnNCVkeHUh?=
COR-L88MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGntdFVKSzVyPUi4Nk4zPiCwTR?=NWj1fFRiW0GQR1XS
NCI-H2126MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTh6Mj64N{BvVQ>?NUiw[ottW0GQR1XS
CAPAN-1NVL1V2VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjZPYNzUUN3ME24PFMvOjlibl2=NGXWU3dUSU6JRWK=
BT-474MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTl|OD6xOEBvVQ>?M3jsN3NCVkeHUh?=
BHYMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTl5NT60PEBvVQ>?Mlu5V2FPT0WU
HT-3M4K4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrFOYdvUUN3ME25PFIvPDFibl2=NUT1ZYJoW0GQR1XS
SK-NEP-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTl6OT60OEBvVQ>?MmC5V2FPT0WU
MS-1MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HTOWlEPTB;OUm0MlY6KG6PMV3TRW5ITVJ?
DOHH-2NGXqWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TXOWlEPTB;MT6wNFAzOSEQvF2=NWD6e2pTW0GQR1XS
NCI-H1304NWTXc4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HofWlEPTB;MT6wNVY1OyEQvF2=MlHQV2FPT0WU
EM-2MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH70fmNKSzVyPUGuNFMxOTZizszNM1;aXHNCVkeHUh?=
MHH-PREB-1NWTUOIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rSV2lEPTB;MT6wPFQ2OSEQvF2=MVnTRW5ITVJ?
KU-19-19NV\TfGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPwZnRKSzVyPUGuNFg2PDFizszNNFrGWnNUSU6JRWK=
NCI-H1648M{Dke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPBTWM2OD1zLkGwOlE3KM7:TR?=MnHCV2FPT0WU
MKN1M2DCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2joW2lEPTB;MT6yNVk5PyEQvF2=NYnWU5lbW0GQR1XS
SNU-449MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTFwMkKyNFgh|ryPNGHqVXRUSU6JRWK=
OAW-42M{e5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fQVmlEPTB;MT6yO|gzPSEQvF2=NWrxbol1W0GQR1XS
769-PM17mPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLGU5h6UUN3ME2xMlI4QTF6IN88US=>NV3OOXlIW0GQR1XS
SW1088MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzEb3ZzUUN3ME2xMlI6PjB5IN88US=>NHzzeZBUSU6JRWK=
GCIYMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\hNpQ{UUN3ME2xMlMxOTN{IN88US=>M3:yO3NCVkeHUh?=
CTV-1NGi3WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHxWYFKSzVyPUGuN|A5KM7:TR?=M4\1T3NCVkeHUh?=
NCI-H1092MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPLTWM2OD1zLkOwPFUh|ryPM4S5PXNCVkeHUh?=
NKM-1M4fOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;kd2lEPTB;MT6zNlU6PyEQvF2=NFv0emZUSU6JRWK=
NCI-H1650MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnNbXNKSzVyPUGuN|M1QDJizszNNF;Ie|RUSU6JRWK=
SW954NULUb4l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrIc5p3UUN3ME2xMlM1ODR6IN88US=>NIHORVFUSU6JRWK=
SW48NFf4WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFni[2JKSzVyPUGuN|Y3OThizszNM3T5SHNCVkeHUh?=
SK-N-DZM{LGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fIPWlEPTB;MT6zOlk1PyEQvF2=NFG0[GxUSU6JRWK=
KMOE-2NXHEZWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwM{m4NVUh|ryPNVjGTZhDW0GQR1XS
NB5MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PhUmlEPTB;MT60NFg6PCEQvF2=MnvHV2FPT0WU
CCRF-CEMNYeweJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;PdWlEPTB;MT60NVEyKM7:TR?=MmjhV2FPT0WU
RH-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\r[pJKSzVyPUGuOFEyOzZizszNNHu4cJpUSU6JRWK=
NCI-H526NHK1XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLKTWM2OD1zLkSzPFI3KM7:TR?=NWjuUHF5W0GQR1XS
697NYf1PWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXnSJZKSzVyPUGuOFQyODRizszNMUPTRW5ITVJ?
J82Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrBNpVCUUN3ME2xMlQ2PzZ4IN88US=>NXizTmNPW0GQR1XS
BE-13MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHCTWM2OD1zLkWwOlcyKM7:TR?=MojDV2FPT0WU
SASMlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nKN2lEPTB;MT61NVYzOiEQvF2=NELXWIJUSU6JRWK=
SCC-25M3\sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnOTWM2OD1zLkWyN|IzKM7:TR?=NVzBWWJ4W0GQR1XS
LAMA-84NFe2NG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTFwNUO4NVUh|ryPNHXpfG1USU6JRWK=
HSC-3M{\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\RN2lEPTB;MT61OFM5KM7:TR?=MknpV2FPT0WU
BT-549NEDyRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\tfmlKSzVyPUGuOVg4PDdizszNNHHSO|RUSU6JRWK=
ML-2NVXlWmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXaZXNKSzVyPUGuOlQxOjlizszNMWXTRW5ITVJ?
BB30-HNCNHjBOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPoTWM2OD1zLk[4PVczKM7:TR?=NEXkWnBUSU6JRWK=
PANC-03-27MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLkTWM2OD1zLkewNVM6KM7:TR?=NWTmRpBKW0GQR1XS
COLO-678MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3NV5VKSzVyPUGuO|M1PDRizszNMXnTRW5ITVJ?
NCI-H1666MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXwTWM2OD1zLke0O|A1KM7:TR?=NHfRXG1USU6JRWK=
NCI-H209MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWK4V5UyUUN3ME2xMlc4OjZ7IN88US=>MnXTV2FPT0WU
EPLC-272HNWfWNI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEP5eWRKSzVyPUGuPFU2PDlizszNNW\GeohEW0GQR1XS
OMC-1M1XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITPO3JKSzVyPUGuPVk5QDhizszNM{DWU3NCVkeHUh?=
HCC70M1H5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTJwMEC4NVUh|ryPM32xdXNCVkeHUh?=
CAL-12TMl3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJwMEG4OlEh|ryPM4\RT3NCVkeHUh?=
TGBC24TKBNV;WU29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTJwMEK5OlEh|ryPM4rEWXNCVkeHUh?=
EKVXMn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXuTFhKSzVyPUKuNFQ6OzlizszNMoOxV2FPT0WU
SW1116NGPI[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJwME[wNFkh|ryPM3LKTnNCVkeHUh?=
NCI-H2009M1;nS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK0OJp6UUN3ME2yMlA3OjF2IN88US=>NGXkOnpUSU6JRWK=
RPMI-8866NUGw[WU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIO1Z3JKSzVyPUKuNFg1QDFizszNNEe1NFVUSU6JRWK=
KARPAS-45Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXmxTpV2UUN3ME2yMlEzPDd7IN88US=>NG[5N21USU6JRWK=
RXF393NGTSNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTJwMUOwN|Yh|ryPMlqxV2FPT0WU
786-0MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYP2fpFbUUN3ME2yMlE5PDB4IN88US=>M{PEXnNCVkeHUh?=
SCC-4NWD3cmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXETWM2OD1{LkKxO|c3KM7:TR?=NXTYNXpzW0GQR1XS
BT-20MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fpNGlEPTB;Mj6yOlc1PCEQvF2=M17EWHNCVkeHUh?=
A498M1H3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmGwTWM2OD1{LkK5OFE2KM7:TR?=M3XF[nNCVkeHUh?=
IGROV-1NYnw[ZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXuTWM2OD1{LkOxNlM4KM7:TR?=M4rhT3NCVkeHUh?=
JVM-3M3S5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJwM{S2OFMh|ryPM1zuNHNCVkeHUh?=
NCI-H2170NHT5NldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Lz[2lEPTB;Mj6zOFc5OyEQvF2=Mn[5V2FPT0WU
EW-18NEjsOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHDTWM2OD1{LkO1OFcyKM7:TR?=NYSzXWx2W0GQR1XS
KU812MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUewdphDUUN3ME2yMlM3Pzd7IN88US=>M4D4NXNCVkeHUh?=
NYMn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LxOWlEPTB;Mj6zO|I4KM7:TR?=MVPTRW5ITVJ?
HTC-C3M{HPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJwNEKyOlch|ryPMXvTRW5ITVJ?
CFPAC-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmT6TWM2OD1{LkSzPFY1KM7:TR?=NV3N[IlbW0GQR1XS
HHNHq4fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJwNEm4OVQh|ryPNV;aTot2W0GQR1XS
MKN7M3PBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJwNkK3OFgh|ryPNF3IW45USU6JRWK=
TE-8MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnX5TWM2OD1{Lk[zOlU{KM7:TR?=MVzTRW5ITVJ?
MC-IXCNGDSS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLEXJVKSzVyPUKuOlQ1PTNizszNM2jJO3NCVkeHUh?=
DMS-79NI\DWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHtb5pKSzVyPUKuOlkzQDRizszNNHWycYhUSU6JRWK=
Detroit562NGm1dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTJwNkm4OFUh|ryPNFKwbnpUSU6JRWK=
HuP-T4MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkW4TWM2OD1{LkeyPFE5KM7:TR?=MXPTRW5ITVJ?
QIMR-WILMl:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{n3W2lEPTB;Mj63OVk2OiEQvF2=NYHsPYZIW0GQR1XS
BB65-RCCMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[xTWM2OD1{LkiwO|E{KM7:TR?=NWqxXm54W0GQR1XS
PC-3MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTXTWM2OD1{LkizN|E4KM7:TR?=MoTlV2FPT0WU
OVCAR-3M1qxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnX5TWM2OD1{Lki1OVk1KM7:TR?=MVfTRW5ITVJ?
KYSE-510NW\iTY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjyWXBlUUN3ME2yMlg3Pzh4IN88US=>M4jsXHNCVkeHUh?=
HC-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnNcohrUUN3ME2yMlk1ODF{IN88US=>NGXMdIJUSU6JRWK=
NCI-H1693NWD6TXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LHUmlEPTB;Mj65OVg6PyEQvF2=MkD1V2FPT0WU
DU-4475Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTJwOUmwOVIh|ryPNYnTU5BrW0GQR1XS
COLO-680NNIXXUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\mTWM2OD1|LkCwOFk2KM7:TR?=NHzJXWlUSU6JRWK=
MN-60NXjsc3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTrUmpKSzVyPUOuNFQ6PzRizszNMUTTRW5ITVJ?
BCPAPNVe0VZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTNwMEiyPVUh|ryPNULzeJdVW0GQR1XS
647-VNV;Ob|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTNwMU[yNkDPxE1?NX7tU2p6W0GQR1XS
HT-1376NXHlOlR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPZUWhUUUN3ME2zMlIxPTB4IN88US=>NEe0XYJUSU6JRWK=
NCI-H1793NWfURphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M164[mlEPTB;Mz6yNVA6QCEQvF2=MlnDV2FPT0WU
SW1463NXjkSnFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnx[YNKSzVyPUOuNlYyQTJizszNMXHTRW5ITVJ?
NCI-H727M{WyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\jOmlEPTB;Mz6zPFU5PCEQvF2=NIrkUWJUSU6JRWK=
LB771-HNCM3zOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LFbGlEPTB;Mz6zPVEzPiEQvF2=MlLRV2FPT0WU
D-542MGNILucHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2r5Z2lEPTB;Mz60OFIzOiEQvF2=NYLVS4FPW0GQR1XS
NTERA-S-cl-D1NICxWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjhcG45UUN3ME2zMlQ1QTV5IN88US=>NYT1cmhSW0GQR1XS
C8166NV3T[2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjpbVVNUUN3ME2zMlQ3PTJzIN88US=>NHPzNGxUSU6JRWK=
639-VM{TxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTNwNUe3PVIh|ryPMm\QV2FPT0WU
TE-1NFHCcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTNwNUmxOlkh|ryPNEjUc4NUSU6JRWK=
OAW-28MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDFXJN7UUN3ME2zMlU6PDJ4IN88US=>M1X0[HNCVkeHUh?=
SK-LU-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DxXGlEPTB;Mz62NFY1PSEQvF2=NVnrXoNIW0GQR1XS
CaR-1M1nLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTNwNkGwOFgh|ryPNV;OOWk2W0GQR1XS
A2780MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPDRmU3UUN3ME2zMlY1ODh7IN88US=>NHHvW4hUSU6JRWK=
C2BBe1M3LqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLRTWM2OD1|Lk[0OFA4KM7:TR?=MWHTRW5ITVJ?
SK-MES-1Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X3[mlEPTB;Mz62OFYyPCEQvF2=NV3kW|B1W0GQR1XS
PANC-10-05M4T6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX71T|VbUUN3ME2zMlczODd{IN88US=>MVnTRW5ITVJ?
J-RT3-T3-5M{jIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfKfnJxUUN3ME2zMlc2PDB4IN88US=>M1PjXnNCVkeHUh?=
ES4NGPlZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;UdVY3UUN3ME2zMlgzOjh4IN88US=>MUfTRW5ITVJ?
NCI-H28M2ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjVTWM2OD1|LkiyPVYyKM7:TR?=NFLLS2lUSU6JRWK=
NCI-H1155MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTXNItKSzVyPUOuPFQyPTlizszNNIixXldUSU6JRWK=
KURAMOCHIM2fuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH65S3pKSzVyPUOuPFYxPTZizszNNUfQV2NlW0GQR1XS
NCI-H69M37RPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzyS4dDUUN3ME2zMlkxOTd6IN88US=>NFT3epFUSU6JRWK=
IST-MES1NXLJe4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfuW2JFUUN3ME2zMlk1ODJ7IN88US=>MYfTRW5ITVJ?
NH-12M2fmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrXe495UUN3ME2zMlk1OTh5IN88US=>NW\0[lJ3W0GQR1XS
JVM-2MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLZTWM2OD1|Lkm0O|UzKM7:TR?=NY\sVmFEW0GQR1XS
EW-16MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[xTWM2OD1|Lkm1OVc4KM7:TR?=M1rtO3NCVkeHUh?=
NCI-H441M3X1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHKPJJOUUN3ME2zMlk4ODF2IN88US=>M{LsWnNCVkeHUh?=
RCC10RGBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[1Upk2UUN3ME20MlAyOjR4IN88US=>MoTRV2FPT0WU
TCCSUPM{XnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLjTFNrUUN3ME20MlEyODVizszNNXO0bGxuW0GQR1XS
HL-60NFT0XJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFi2eIRKSzVyPUSuNVIzPDFizszNMVnTRW5ITVJ?
EW-11NU[4blBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTzTWM2OD12LkGzNlYyKM7:TR?=MUjTRW5ITVJ?
KARPAS-299MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LFfWlEPTB;ND6zNVAyOyEQvF2=MX3TRW5ITVJ?
SNU-C2BM37mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml71TWM2OD12LkO0Olg3KM7:TR?=NUL0OnpKW0GQR1XS
LU-139M1PpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\pTWM2OD12LkO3NlQ4KM7:TR?=NXzpfpl6W0GQR1XS
HCC1937NXPl[XB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPDTWM2OD12LkO3PVk{KM7:TR?=NF7YemRUSU6JRWK=
GR-STNG\sfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P3VGlEPTB;ND60N|E5KM7:TR?=MWnTRW5ITVJ?
SK-OV-3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M372UWlEPTB;ND60OlA1OiEQvF2=MUjTRW5ITVJ?
A172NYPNUpU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXntTWlRUUN3ME20MlU2PTJzIN88US=>M2HRcXNCVkeHUh?=
NB10MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTRwNUm3PFEh|ryPMmfIV2FPT0WU
P30-OHKMnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3r2[mlEPTB;ND64NVkzQSEQvF2=NIfYfZpUSU6JRWK=
KYSE-520NG\xNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTsTWM2OD12Lki4NFE5KM7:TR?=MXHTRW5ITVJ?
KNS-62NIjPd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnGTWM2OD12LkmwPFA4KM7:TR?=M{jae3NCVkeHUh?=
ES1NVW5WmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTDTWM2OD12Lkm2NFM2KM7:TR?=M4HIT3NCVkeHUh?=
KOSC-2M{\obGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTRwOUm5OVkh|ryPNV31emxbW0GQR1XS
TE-9M3r1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTVwMEG1NlUh|ryPMoPGV2FPT0WU
NCI-H1838NHnkN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPvc4pRUUN3ME21MlAzODd4IN88US=>MnfvV2FPT0WU
KP-N-YNMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\1[2lEPTB;NT6xNlU6OSEQvF2=NYLjPJQ5W0GQR1XS
ALL-POM3PudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTVwMkK1PFch|ryPNWOxVYE2W0GQR1XS
NOMO-1MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDVTWM2OD13LkKzNVc3KM7:TR?=NX7oOFZFW0GQR1XS
CGTH-W-1M37BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;kZXV4UUN3ME21MlM5PTh2IN88US=>MmDEV2FPT0WU
ATN-1MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rlWmlEPTB;NT60NVE5PCEQvF2=NGG0bJVUSU6JRWK=
AGSNV3hWnUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXv6ToxzUUN3ME21MlQ6PjF6IN88US=>NGj1bWJUSU6JRWK=
SW13NYnJXodUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTVwNUOyOlUh|ryPMlm4V2FPT0WU
SW1990MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HQU2lEPTB;NT62NlI5PSEQvF2=MVHTRW5ITVJ?
BFTC-905M3LZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHCTWM2OD13Lk[1PFc5KM7:TR?=NGL6dZBUSU6JRWK=
RMG-IMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTVwNkW5OFIh|ryPM{[1U3NCVkeHUh?=
HD-MY-ZMm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml62TWM2OD13Lk[4OVgyKM7:TR?=MWTTRW5ITVJ?
HCC1187NGjKfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDCb5F7UUN3ME21MlcyODN{IN88US=>NXy5WnV[W0GQR1XS
HCC2998MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7STWM2OD13LkexPFc4KM7:TR?=M{XsWXNCVkeHUh?=
RT-112MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PWW2lEPTB;NT65NFI1PSEQvF2=NEfJdXBUSU6JRWK=
CAKI-1NIj1UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTZTWM2OD14LkCwPVg2KM7:TR?=MmDyV2FPT0WU
HDLM-2NH\ZXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTZwMEG0PFkh|ryPM3e0cnNCVkeHUh?=
TE-10NEPX[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mne2TWM2OD14LkC0PFM{KM7:TR?=MlfiV2FPT0WU
KE-37Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVi3fY5CUUN3ME22MlA4OjV6IN88US=>MmHQV2FPT0WU
RCM-1NWDJPY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDnPZBTUUN3ME22MlA4PzF7IN88US=>MUjTRW5ITVJ?
MewoM17KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPaTWM2OD14LkGxOFg4KM7:TR?=Ml;XV2FPT0WU
L-428NEPPSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTZwMUiwN|ch|ryPMoTxV2FPT0WU
8-MG-BANELW[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\4VnZpUUN3ME22MlE6Ozd7IN88US=>NXfVV5BIW0GQR1XS
SK-MEL-28MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTZwMkC5Olch|ryPMY\TRW5ITVJ?
VA-ES-BJNGPoe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFS1[2lKSzVyPU[uN|A1PjJizszNM2\3cHNCVkeHUh?=
CAL-120MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnVWpV6UUN3ME22MlQ2OTZ{IN88US=>NWrnelRYW0GQR1XS
GAMGNEGyUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVm3TGNbUUN3ME22MlUxPjJizszNMWHTRW5ITVJ?
MSTO-221HM2PUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33mOWlEPTB;Nj61NVE4KM7:TR?=MX;TRW5ITVJ?
GCTM3jKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmGyTWM2OD14LkWzN|g4KM7:TR?=NYPKdnBoW0GQR1XS
SH-4NIPKeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\aRmlEPTB;Nj61PFg1PCEQvF2=NIPGO2tUSU6JRWK=
Calu-3NH31NmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2WyWmlEPTB;Nj62OVU3QCEQvF2=MXjTRW5ITVJ?
SK-HEP-1MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXtRW5KSzVyPU[uO|E4PTNizszNNV3uO25pW0GQR1XS
PFSK-1NXXMdoNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jPRWlEPTB;Nj63N|Q4QCEQvF2=M{fIPHNCVkeHUh?=
NB12M{HpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7EZW44UUN3ME22Mlc5PDB2IN88US=>NX\uXm5bW0GQR1XS
A388MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljyTWM2OD14Lki5OVIh|ryPM{LVeHNCVkeHUh?=
KLENE[5VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q2OWlEPTB;Nj65OlUyPiEQvF2=MmS2V2FPT0WU
TE-11NXXVWFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrNTWM2OD15LkC0PVY4KM7:TR?=MmHUV2FPT0WU
NCI-H2405M{fvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7MVW9KSzVyPUeuNFg{QTNizszNMmj0V2FPT0WU
OVCAR-4MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zSV2lEPTB;Nz6xOVM2KM7:TR?=M1LWXXNCVkeHUh?=
KP-N-YSMmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mny1TWM2OD15LkG4NVQh|ryPMkfXV2FPT0WU
NOS-1MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWW2R3NWUUN3ME23MlI2QDJ6IN88US=>MofQV2FPT0WU
DMS-114NW\H[JlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknZTWM2OD15LkK5OlMyKM7:TR?=NUPoZ3RGW0GQR1XS
NCI-H2030MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInuRnpKSzVyPUeuN|M3QThizszNNXmxeZhoW0GQR1XS
HELMmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTdwM{e1NlEh|ryPNXfJZWQ1W0GQR1XS
CAL-62MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfiTWM2OD15LkO5PFY3KM7:TR?=M3z4[HNCVkeHUh?=
COLO-668M3XhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPjPHpKSzVyPUeuOFM6PjdizszNMkDnV2FPT0WU
SKG-IIIaMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT5UoFnUUN3ME23MlQ2OzhzIN88US=>MVHTRW5ITVJ?
HCC1419NW[2dZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4n4OWlEPTB;Nz60Olg{OyEQvF2=MV7TRW5ITVJ?
OS-RC-2MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzIWFZkUUN3ME23MlQ6QDl2IN88US=>Ml7WV2FPT0WU
COLO-829MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPqeW1KSzVyPUeuOlY1PjNizszNMoLpV2FPT0WU
NB13MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nmRWlEPTB;Nz64NlY3PyEQvF2=NWfIflJCW0GQR1XS
DK-MGM{jWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELRdHBKSzVyPUeuPFMzODFizszNNGWzbppUSU6JRWK=
SHP-77MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnzWJBsUUN3ME23Mlg3PjV|IN88US=>NY\ZT|lNW0GQR1XS
NCI-H661NWfTeppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TteGlEPTB;OD6wOVg3PyEQvF2=NX3zVHA6W0GQR1XS
AM-38M1rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRThwMU[yPEDPxE1?NXjjO4RJW0GQR1XS
VM-CUB-1NGHKZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDMNWFKSzVyPUiuNVcxOjlizszNMl;zV2FPT0WU
KYSE-70NV7YNXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHJTWM2OD16LkG5O|YyKM7:TR?=NGTKNFdUSU6JRWK=
5637NHPUb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRThwM{GwOVUh|ryPMWPTRW5ITVJ?
TGBC11TKBM2P2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjQV405UUN3ME24MlQ3OTZ2IN88US=>MUjTRW5ITVJ?
EGI-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHH2NYRKSzVyPUiuOlAxQDhizszNM1u5NXNCVkeHUh?=
D-392MGMkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;N[4xWUUN3ME24MlY3OjF2IN88US=>M1zT[XNCVkeHUh?=
A673NYjONIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLxWlRqUUN3ME24MlY4PjFzIN88US=>M3\4SXNCVkeHUh?=
COLO-792M1O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHXTWM2OD16Lke0PVQ3KM7:TR?=NGGxNXZUSU6JRWK=
NCI-H1792NG[1T3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDj[mhyUUN3ME24Mlg5QTB|IN88US=>MnTJV2FPT0WU
LS-1034Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRThwOUS2OVIh|ryPMnzWV2FPT0WU
D-566MGMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknQTWM2OD17LkCxPFEh|ryPMnTaV2FPT0WU
NCI-H226MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLSTWM2OD17LkC5JO69VQ>?M{fTV3NCVkeHUh?=
ChaGo-K-1M1q2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmSyTWM2OD17LkGwOVc6KM7:TR?=NXrOeYprW0GQR1XS
NCI-H2228M2\3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTlwMUGwPFEh|ryPM4XNUHNCVkeHUh?=
RPMI-8226NGfUR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXhfHZKSzVyPUmuNVE{ODRizszNNGm3cZdUSU6JRWK=
BFTC-909MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jxUWlEPTB;OT6xPFI6PyEQvF2=M3nsbHNCVkeHUh?=
HPAF-IINFfFelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTlwMkK1NVgh|ryPM1iyOHNCVkeHUh?=
Capan-2NVHae3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjJ[FJiUUN3ME25MlQxOTB7IN88US=>NF3W[JhUSU6JRWK=
IA-LMNFXBfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TjWGlEPTB;OT60NVk3PiEQvF2=MUfTRW5ITVJ?
KP-4NXi4TYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTlwNEi4N|gh|ryPNWPV[mZ{W0GQR1XS
A101DMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj2Xo9SUUN3ME25MlUyPzF7IN88US=>MV\TRW5ITVJ?
EFO-21NYrOOppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3j0RmlEPTB;OT61PFc{PSEQvF2=M3P5d3NCVkeHUh?=
C32NX;uR4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrGdo5KSzVyPUmuOlM{PCEQvF2=NXmyNG9XW0GQR1XS
SW837M3q0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXv[oRKSzVyPUmuPFQ5OiEQvF2=NUm1cWJHW0GQR1XS
OCI-AML2NF72O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDHV2tKSzVyPUmuPFY6PiEQvF2=MlXVV2FPT0WU
NCI-H1355NGO4T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnmxTWM2OD17Lkm0NFg5KM7:TR?=M3fDO3NCVkeHUh?=
NCI-H2342Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljNTWM2OD1zMD6wNVU2KM7:TR?=NEW3fFFUSU6JRWK=
A204NIHtSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFyLkC0OlYh|ryPMmnDV2FPT0WU
CAL-51NIPJO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f1TGlEPTB;MUCuNFg4PyEQvF2=MWHTRW5ITVJ?
HCE-4MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFviXnhKSzVyPUGwMlEyOjJizszNM1:xOXNCVkeHUh?=
NCI-H810NHf1dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV73cpR7UUN3ME2xNE4yPTl5IN88US=>MWjTRW5ITVJ?
DJM-1MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTaR3dKSzVyPUGwMlE4OzJizszNM2\mVnNCVkeHUh?=
SK-UT-1NFTrfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTFyLkK1O|Qh|ryPMVnTRW5ITVJ?
U031NF:5V5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDCTWM2OD1zMD6yOlg3KM7:TR?=MVzTRW5ITVJ?
YH-13MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWiyWZNlUUN3ME2xNE4{ODV5IN88US=>MUPTRW5ITVJ?
K5NHzGNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37xPWlEPTB;MUCuN|M6PSEQvF2=NUW4fJNjW0GQR1XS
HEC-1NF\6SXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjFZllyUUN3ME2xNE41ODhzIN88US=>NEL5TXVUSU6JRWK=
A2058MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFyLkW0PVEh|ryPNETwXoJUSU6JRWK=
SW962MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLtTWM2OD1zMD62NlA1KM7:TR?=NVXn[ItmW0GQR1XS
VMRC-RCZMnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFyLk[3OFkh|ryPMXrTRW5ITVJ?
D-336MGM1v6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDSO3JKSzVyPUGwMlcxODVizszNM3HRfnNCVkeHUh?=
LXF-289NGq5eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFyLke5Olch|ryPNGPjO5ZUSU6JRWK=
SW900MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjSfFBKSzVyPUGwMlgzOjhizszNNWC2OoFUW0GQR1XS
K-562M1fufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTFyLkizPVUh|ryPNXviWW5YW0GQR1XS
HCC38MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTZNHhKSzVyPUGwMlk4OTZizszNMWDTRW5ITVJ?
SF-295MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFyLkm5NFIh|ryPNYfaR2N7W0GQR1XS
LB831-BLCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFzLkK1OVYh|ryPM4fq[nNCVkeHUh?=
FTC-133Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX34emRTUUN3ME2xNU4{ODhzIN88US=>MXfTRW5ITVJ?
HCC1954MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj1TWpTUUN3ME2xNU41OzZizszNNILLTnhUSU6JRWK=
GOTOMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXft[m1tUUN3ME2xNU42OjB4IN88US=>M1;DTHNCVkeHUh?=
LS-411NM1;3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTFzLk[xNFEh|ryPNV7XUJBHW0GQR1XS
RPMI-7951NVrISVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUizT45nUUN3ME2xNU43OzR6IN88US=>NF\6[GJUSU6JRWK=
NCI-H1299NFXudVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3tTWM2OD1zMT62OlQ4KM7:TR?=MonyV2FPT0WU
MLMAMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLyTWM2OD1zMT62PVk4KM7:TR?=NEjmVXFUSU6JRWK=
MMAC-SFNYDWZ4piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjCSmhFUUN3ME2xNU44OjV{IN88US=>M{\YdHNCVkeHUh?=
UM-UC-3Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fWbWlEPTB;MUGuO|QzOSEQvF2=MXjTRW5ITVJ?
SCC-9Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTFzLkixOVEh|ryPNFHsUnpUSU6JRWK=
HOSM1;Rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTaPHNDUUN3ME2xNU45Pjh|IN88US=>NHzMeJJUSU6JRWK=
OE19MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojGTWM2OD1zMT65N|Y4KM7:TR?=NV\WWZdHW0GQR1XS
Mo-TNV\ONG85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjLdmVTUUN3ME2xNU46PTRzIN88US=>MXvTRW5ITVJ?
CAMA-1MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTF{LkG2N|Mh|ryPNEKyeWhUSU6JRWK=
U-118-MGMorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3[1e2lEPTB;MUKuNlQ1OSEQvF2=NYfYRlY1W0GQR1XS
KS-1Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrFdFgxUUN3ME2xNk4zQDN{IN88US=>M4i3fXNCVkeHUh?=
JARNEHPTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW[0V5JSUUN3ME2xNk4{OzZ7IN88US=>MWTTRW5ITVJ?
ABC-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e2SmlEPTB;MUKuN|QyKM7:TR?=NX:2UXVGW0GQR1XS
DaoyNUHlbIc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXtTmhKSzVyPUGyMlQ2PDJizszNNWDP[G9kW0GQR1XS
C3AMlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF{LkW3PFUh|ryPMmn5V2FPT0WU
GT3TKBNF;4bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITRZo1KSzVyPUGyMlY{OjdizszNMV7TRW5ITVJ?
DMS-273MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTF{Lki2N|Mh|ryPNFvVXWRUSU6JRWK=
G-361M2XJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXexNXFRUUN3ME2xNk46OTJ7IN88US=>M1LHZXNCVkeHUh?=
RH-18Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjrS4ZHUUN3ME2xN{4zQTZ{IN88US=>NIPJNmxUSU6JRWK=
SN12CNGn1fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWiyTXVDUUN3ME2xN{4{QDB6IN88US=>NHy5S2pUSU6JRWK=
NCI-H1993MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHFTWM2OD1zMz60Nlg2KM7:TR?=MlS1V2FPT0WU
LOXIMVINFWwR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXCRlFKSzVyPUGzMlYyPTFizszNNIHse|NUSU6JRWK=
SK-PN-DWMn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DYdmlEPTB;MUOuPFQzPyEQvF2=M2TFdHNCVkeHUh?=
KALS-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTF|Lki1NlUh|ryPMUDTRW5ITVJ?
LAN-6M{XMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDtZWVKSzVyPUG0MlI2OyEQvF2=NH7DbotUSU6JRWK=
A549NVP1TZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHq0UIlKSzVyPUG0MlQ4OTJizszNMli2V2FPT0WU
RDMmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjJTWM2OD1zND60PFE{KM7:TR?=NFW0OFdUSU6JRWK=
TGBC1TKBMnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTF2Lk[2NVUh|ryPNISwOFdUSU6JRWK=
NCI-H630NXLETVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\2U2lEPTB;MUSuPVQ3PyEQvF2=NF\rWXVUSU6JRWK=
MIA-PaCa-2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXOxdVkxUUN3ME2xOE46PjlizszNMn\sV2FPT0WU
NCI-H1755MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\pfldsUUN3ME2xOE46QTV|IN88US=>NFO5Uo1USU6JRWK=
MOLT-4M1jPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnK4TWM2OD1zNT6wOFk4KM7:TR?=NHr0e3hUSU6JRWK=
CW-2NWHu[Iw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYX1ZldVUUN3ME2xOU4yPDJzIN88US=>M2PFVnNCVkeHUh?=
COLO-320-HSRNGjIdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTF3LkWzNFch|ryPNHLSe5RUSU6JRWK=
UMC-11NHLn[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nl[mlEPTB;MUWuO|UzOyEQvF2=M3ToOXNCVkeHUh?=
MCF7NUTpSphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TSVGlEPTB;MUWuPFE1PSEQvF2=NFzTU4xUSU6JRWK=
NCI-H23MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Xmc2lEPTB;MUWuPFQ{QCEQvF2=M37qenNCVkeHUh?=
HuCCT1NIntbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13aUGlEPTB;MUWuPFc1KM7:TR?=MkHlV2FPT0WU
MPP-89MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF3Lkm0NVch|ryPMWLTRW5ITVJ?
HT55NVOxdnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYW0RmdYUUN3ME2xOU46PDd6IN88US=>Mk\lV2FPT0WU
no-11NH7ucGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF3Lkm2OlMh|ryPNV\CVow{W0GQR1XS
GP5dM1rIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTF4LkKxPFch|ryPMV;TRW5ITVJ?
BHT-101MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\oPG1KSzVyPUG2MlI1OzlizszNMVPTRW5ITVJ?
M059JMnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfUU2dpUUN3ME2xOk4zQDRizszNMYDTRW5ITVJ?
D-283MEDM3zzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLNTWM2OD1zNj60NlA6KM7:TR?=M3TTfHNCVkeHUh?=
BENM3\JXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXWVFFOUUN3ME2xOk42OTV3IN88US=>NWPJXYZrW0GQR1XS
LB373-MEL-DMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HncmlEPTB;MU[uO|I{OiEQvF2=NWX4fm5tW0GQR1XS
MEL-HOMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3vcm1PUUN3ME2xOk45QDV2IN88US=>NEH5RZpUSU6JRWK=
GI-ME-NMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HGUmlEPTB;MU[uPVA{OiEQvF2=MmXmV2FPT0WU
RKONIr2cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NID0SFlKSzVyPUG3MlA4PDhizszNNGHrUJhUSU6JRWK=
MZ2-MELMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;GRWlEPTB;MUeuNVM{KM7:TR?=NGjtO3pUSU6JRWK=
NCI-H1573M3fEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonmTWM2OD1zNz6yPFI3KM7:TR?=MlXyV2FPT0WU
NCI-H1581NUL2Z3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;aO2lEPTB;MUeuOFQyOSEQvF2=NVvFO4o3W0GQR1XS
NCI-H747NY\PO4tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTF5LkWyPVch|ryPM1TQcXNCVkeHUh?=
SW1783MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mke1TWM2OD1zNz62OFE2KM7:TR?=MnPVV2FPT0WU
Calu-6NGTMe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHMTWM2OD1zNz62O|gzKM7:TR?=NVXMUIhHW0GQR1XS
SF268NHX3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTiTWM2OD1zNz62PVY6KM7:TR?=MkPiV2FPT0WU
ES8NHfYRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnNRY1KSzVyPUG3Mlg2QTNizszNMYTTRW5ITVJ?
KM-H2M3Hsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHNdHdKSzVyPUG3Mlk1OTFizszNM{jTOHNCVkeHUh?=
D-502MGMl;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTF5Lkm4NFgh|ryPNVy3O|E3W0GQR1XS
HLENYnDWI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVH2RYV3UUN3ME2xPE4{OTR6IN88US=>M{nx[3NCVkeHUh?=
SW982MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3TPWdKSzVyPUG4MlQxPzVizszNM{\MfnNCVkeHUh?=
MDA-MB-361NYnUT2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYP3W3VRUUN3ME2xPE42PTh6IN88US=>NGW4VYtUSU6JRWK=
NCI-H1563NWrkWGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3:4b2lEPTB;MUiuO|EzPCEQvF2=MVPTRW5ITVJ?
MFE-280MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zKSmlEPTB;MUiuO|I6OyEQvF2=MmfyV2FPT0WU
U251NWO4UHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTF6LkezOFch|ryPM1LHV3NCVkeHUh?=
KNS-42NU\H[ZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnaTWM2OD1zOD64NFE2KM7:TR?=NXzIfFc6W0GQR1XS
U-266Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvpTWM2OD1zOD64OlQ6KM7:TR?=MWjTRW5ITVJ?
OVCAR-8Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvQTWM2OD1zOD65Nlc3KM7:TR?=NV71TFVlW0GQR1XS
MFH-inoNFrQXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7KbnZKSzVyPUG4Mlk3PjlizszNMYrTRW5ITVJ?
D-263MGM4e2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvVfpBKSzVyPUG5MlAyPzJizszNM1\aRXNCVkeHUh?=
NCI-H1437NY\GfmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mke1TWM2OD1zOT6wOFY4KM7:TR?=NHS5RotUSU6JRWK=
NCI-H1048M1y3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnqNFJMUUN3ME2xPU4zOzJ4IN88US=>MkjCV2FPT0WU
NCI-H446MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\tSJFKSzVyPUG5MlM2QDlizszNMlP4V2FPT0WU
NCI-N87NIr5SGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:2SpVbUUN3ME2xPU42QTl{IN88US=>NIPie5dUSU6JRWK=
WM-115MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTkTWM2OD1zOT62O|c1KM7:TR?=MX;TRW5ITVJ?
HuH-7MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkftTWM2OD1zOT63OFIyKM7:TR?=NH;kW3VUSU6JRWK=
NCI-H650M2X5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7qTWM2OD1zOT63OVA5KM7:TR?=NHXMcldUSU6JRWK=
TYK-nuNWX6fIZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jtdmlEPTB;MUmuPFM4QCEQvF2=M2m3UnNCVkeHUh?=
BeckerNFPzS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fPU2lEPTB;MUmuPFU1PyEQvF2=MVXTRW5ITVJ?
BB49-HNCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTF7LkmyJO69VQ>?Mmq1V2FPT0WU
HGC-27NFT0cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPafHREUUN3ME2yNE4yOzl2IN88US=>NIqx[m9USU6JRWK=
SiHaNEC4PZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJyLkO3NVIh|ryPM1\qeXNCVkeHUh?=
LB2518-MELMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n1bWlEPTB;MkCuN|c{QSEQvF2=M2fq[nNCVkeHUh?=
TE-5M2Ds[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvlZYhKSzVyPUKwMlc1QDJizszNNX7LXlY{W0GQR1XS
IST-SL1MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvWXY9XUUN3ME2yNE44QDd7IN88US=>MkPyV2FPT0WU
A375Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1j2cWlEPTB;MkGuNFU3PyEQvF2=NWTmbZlKW0GQR1XS
MC116NFjGd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHyzR|VKSzVyPUKxMlA4OjNizszNMYTTRW5ITVJ?
GI-1NXjlcIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJzLkG3JO69VQ>?M2HCUXNCVkeHUh?=
HOP-62NHq3eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDWTWM2OD1{MT6yO|g1KM7:TR?=NVjXcHVYW0GQR1XS
PA-1NUjLeJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHRTWM2OD1{MT6yO|g4KM7:TR?=M1nHeHNCVkeHUh?=
HTNVLsOYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1myN2lEPTB;MkGuOFM{OSEQvF2=NYXZV4xIW0GQR1XS
HUTU-80M2[4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnjRXRKSzVyPUKxMlQ{OzZizszNM{[3NXNCVkeHUh?=
NCI-H1975M{DENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjHSllSUUN3ME2yNU41PjFizszNNHzuSIxUSU6JRWK=
GAKMl7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrwN4tKSzVyPUKxMlQ6QSEQvF2=NGPpR4NUSU6JRWK=
SK-N-ASMmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPhbo9SUUN3ME2yNU42PjF7IN88US=>MknXV2FPT0WU
OE33NInsV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;OcJZKSzVyPUKxMlYxPDZizszNNIPjbVZUSU6JRWK=
YKG-1Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPjTWM2OD1{MT62OVQ2KM7:TR?=MkHzV2FPT0WU
CAL-85NV76fHF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjne|JKSzVyPUKxMlk{ODVizszNNHO3TXRUSU6JRWK=
NCI-H2347MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDUUIZKSzVyPUKxMlk1OjhizszNMXLTRW5ITVJ?
PANC-08-13M1G4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jlcmlEPTB;MkKuNFEyQSEQvF2=NWi3ZWZTW0GQR1XS
SK-N-FINVTaUFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELPRW5KSzVyPUKyMlMxPzRizszNNID0XGdUSU6JRWK=
NEC8MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFW5eWFKSzVyPUKyMlUxPzhizszNNGjGZYtUSU6JRWK=
AN3-CAMknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XiPGlEPTB;MkKuOlA5PCEQvF2=MojlV2FPT0WU
HuO9MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP1TWM2OD1{Mj63N|k3KM7:TR?=NVjKXmRwW0GQR1XS
COLO-800NIXPO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPBb21SUUN3ME2yNk44PjV|IN88US=>M2HYOHNCVkeHUh?=
HT-29NEm1TYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjuR3AyUUN3ME2yNk45QDJ|IN88US=>NYfnbpB{W0GQR1XS
OC-314MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJ{Lki4OFUh|ryPNGHvRXBUSU6JRWK=
G-401NGn2T3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XYT2lEPTB;MkOuNFQ3OiEQvF2=NVLHdWZlW0GQR1XS
Saos-2NF;NVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fKXmlEPTB;MkOuOVE5OiEQvF2=NIX3R2xUSU6JRWK=
UACC-62NYmxcHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET1UYVKSzVyPUKzMlU5OzNizszNNUHZN3ZQW0GQR1XS
D-247MGM4rhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYj4N2hyUUN3ME2yN{44QTN7IN88US=>M4PYPHNCVkeHUh?=
COLO-741NGr4fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVe3bVlwUUN3ME2yN{46PTZ3IN88US=>NFKzO3FUSU6JRWK=
ES3M2nLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHyb4xYUUN3ME2yOE4xODJ|IN88US=>MlHvV2FPT0WU
LNCaP-Clone-FGCMnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3yS2szUUN3ME2yOE4xOjFzIN88US=>NVTxOIhNW0GQR1XS
SW1710NXHQXlllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTJ2LkG1NFYh|ryPNIPMUmRUSU6JRWK=
LU-99ANXHldXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTJ2LkG4OFEh|ryPNWKzeJBsW0GQR1XS
HOP-92MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ2LkeyOUDPxE1?M{\p[HNCVkeHUh?=
LS-123NX:0SZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TyTmlEPTB;MkSuPVYyPCEQvF2=Mn;ZV2FPT0WU
T84MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTa[m44UUN3ME2yOE46PzZ3IN88US=>M3\BZnNCVkeHUh?=
HCT-116NV7sXFRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJ3LkSxPFYh|ryPMVzTRW5ITVJ?
M14MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX65UYlTUUN3ME2yOU41PDR5IN88US=>M{[yT3NCVkeHUh?=
OCUB-MM2W3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjiTWM2OD1{NT60OFU3KM7:TR?=NVyy[HhKW0GQR1XS
MKN45Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTV[ndxUUN3ME2yOU43OzF3IN88US=>M3vIR3NCVkeHUh?=
LCLC-97TM1NVTyWZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITxN2xKSzVyPUK1MlczQDVizszNNITDVVNUSU6JRWK=
RVH-421M3PrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTJ3LkixOlEh|ryPMVXTRW5ITVJ?
NKS-81-FDNX2yPVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJ3LkmwNlEh|ryPNEDGTGVUSU6JRWK=
NCI-H596NWnvXmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULvepkxUUN3ME2yOk4xPDh5IN88US=>Mn3wV2FPT0WU
GB-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzHPWlKSzVyPUK2MlE5PzlizszNNITOdYRUSU6JRWK=
ZR-75-30M2rXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ4LkKyPVch|ryPMVPTRW5ITVJ?
U-2-OSNHPZUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrHU4VjUUN3ME2yOk4{PzV5IN88US=>MVPTRW5ITVJ?
HuP-T3MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljzTWM2OD1{Nj62NVAzKM7:TR?=NFvVOVJUSU6JRWK=
MOLT-16M1LxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX3TWM2OD1{Nj62NVY3KM7:TR?=Mk\QV2FPT0WU
U-87-MGM3;TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;wOWlEPTB;Mk[uO|Q{QCEQvF2=MWLTRW5ITVJ?
8505CMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3K3cWlEPTB;Mk[uPVEzPiEQvF2=MYTTRW5ITVJ?
SK-MEL-3NELjb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4X3dmlEPTB;Mk[uPVgzQCEQvF2=Mlq4V2FPT0WU
COLO-824NYTVXmU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3T1XGlEPTB;MkeuNlE6PSEQvF2=MUjTRW5ITVJ?
EW-1NXKzcoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvJZ|B3UUN3ME2yO{4{PTV2IN88US=>M2e5eHNCVkeHUh?=
UACC-257MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnkRZVKSzVyPUK3MlM5ODRizszNM4rrWnNCVkeHUh?=
Hs-578-TMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfjd2lsUUN3ME2yO{42Ojl7IN88US=>MVfTRW5ITVJ?
UACC-893MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT4RpRMUUN3ME2yO{43PjNzIN88US=>NFvtTmdUSU6JRWK=
MHH-NB-11NYjnV4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TZXWlEPTB;MkeuPFAxPyEQvF2=Ml7mV2FPT0WU
KYSE-410MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTPSpFPUUN3ME2yPE4zPzd7IN88US=>MmHQV2FPT0WU
SF126NYLucmp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PJR2lEPTB;MkiuO|Q{PSEQvF2=NYPnZ|NLW0GQR1XS
HT-144MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTJ7LkOzOlIh|ryPMUPTRW5ITVJ?
SW1573NXXnNnI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmO3TWM2OD1{OT6zOVA6KM7:TR?=MnTwV2FPT0WU
SW620NVHmcXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTuUGZKSzVyPUK5MlM3PDFizszNMXrTRW5ITVJ?
SCHNEHGNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\BbWlEPTB;MkmuPFg{OSEQvF2=M1LiZ3NCVkeHUh?=
EW-22M{PZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvmTZEzUUN3ME2zNE4yQTZ7IN88US=>NV3nTYxbW0GQR1XS
H4NWTPSldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTNyLkS2OVQh|ryPM1HWV3NCVkeHUh?=
CAS-1NH;WOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDGTWM2OD1|MD63PFU6KM7:TR?=M4m3VHNCVkeHUh?=
MG-63M3vDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTNyLki0O|gh|ryPNFvSZ2tUSU6JRWK=
MDA-MB-415M2S4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofQTWM2OD1|MT6xO|U{KM7:TR?=NHLy[WtUSU6JRWK=
NCI-H1395NFH4bXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTNzLkKzNlgh|ryPMoHEV2FPT0WU
Ca-SkiNGn0V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{foemlEPTB;M{GuN|E4PyEQvF2=NUDMNmdiW0GQR1XS
BxPC-3MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jMPGlEPTB;M{GuN|czQSEQvF2=MkjXV2FPT0WU
A3-KAWM1rvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLVTWM2OD1|MT60OFcyKM7:TR?=MXrTRW5ITVJ?
T-24MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHW3cplKSzVyPUOxMlc{PjJizszNM1WxUnNCVkeHUh?=
NCI-H2029M{XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDXTWM2OD1|MT63O|Y2KM7:TR?=NELoOHRUSU6JRWK=
YAPCNVXhb3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrrTWM2OD1|Mj6wOFA4KM7:TR?=NVn3R4RlW0GQR1XS
SK-MEL-2M1rWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fJ[WlEPTB;M{KuNFUzKM7:TR?=MorsV2FPT0WU
LS-513MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vTNGlEPTB;M{KuNVE5PyEQvF2=NXXnVXJrW0GQR1XS
AsPC-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3JTWM2OD1|Mj6zOlA2KM7:TR?=M{HkZ3NCVkeHUh?=
KYSE-150MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDqTWM2OD1|Mj6zO|c{KM7:TR?=M{jCdHNCVkeHUh?=
NCI-H520M3[5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTN{LkS0PFIh|ryPMUDTRW5ITVJ?
JEG-3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjoTWM2OD1|Mz6wPVcyKM7:TR?=MnT2V2FPT0WU
GMS-10M3LmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfNTWM2OD1|Mz6zNFA1KM7:TR?=NYfqT3pJW0GQR1XS
HT-1080Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\RTWM2OD1|Mz6zPUDPxE1?NXPrfpM1W0GQR1XS
NCI-H1651M1W2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDYcZFHUUN3ME2zN{4{QTZizszNM3fiSnNCVkeHUh?=
NCI-H2122MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPDTWM2OD1|Mz61OVc1KM7:TR?=Mo\WV2FPT0WU
ES5M{PZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\KTWM2OD1|Mz63NlkzKM7:TR?=NFfzN3BUSU6JRWK=
8305CMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTN|Lkm5N|ch|ryPM2jpUXNCVkeHUh?=
KM12MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXSb45QUUN3ME2zOE4xPDd6IN88US=>NICxTnpUSU6JRWK=
HCT-15NGPpdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPJTWM2OD1|ND6xNlch|ryPNG\MSm9USU6JRWK=
OVCAR-5Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHPTWM2OD1|ND6yNVgzKM7:TR?=MUfTRW5ITVJ?
NCI-H2291Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj0TWM2OD1|ND6yOFczKM7:TR?=MnrsV2FPT0WU
CP50-MEL-BMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXq3R|RbUUN3ME2zOE43PTl{IN88US=>NI\MNmVUSU6JRWK=
C-33-ANIXleZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTN2Lk[4OVch|ryPM2nzU3NCVkeHUh?=
NCI-H2452MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjJTpBKSzVyPUO0Mlc5QDJizszNMYnTRW5ITVJ?
MDA-MB-157M4PVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvjephlUUN3ME2zOE45OTl|IN88US=>NH\EW2NUSU6JRWK=
LN-405M{foOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTN3LkSzNFgh|ryPNHnmfmdUSU6JRWK=
MDA-MB-231NU\uNHhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLLRnhSUUN3ME2zOU42ODV2IN88US=>M17seXNCVkeHUh?=
EW-24NW[2SYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTN3Lk[zN|Uh|ryPMnvxV2FPT0WU
MKN28M3H4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nIT2lEPTB;M{WuPFI{PiEQvF2=M3zTfHNCVkeHUh?=
KINGS-1M{ThcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Poc2lEPTB;M{WuPFQ{PCEQvF2=NHL0WGZUSU6JRWK=
LC-2-adMlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TBZ2lEPTB;M{[uOlk6KM7:TR?=MWjTRW5ITVJ?
IGR-1NEPmOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTN4LkewO|Uh|ryPNFXXcGlUSU6JRWK=
SW626M3e2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrkTWM2OD1|Nz6wOFE4KM7:TR?=MXPTRW5ITVJ?
ONS-76NHXlbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfpU45sUUN3ME2zO{4yOzB7IN88US=>NWTqUldGW0GQR1XS
T98GMlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT5WHl5UUN3ME2zO{45PjN3IN88US=>M3OxV3NCVkeHUh?=
NB14NFfnOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTN6LkS1OFQh|ryPMmq5V2FPT0WU
D-423MGMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2K1d2lEPTB;M{iuOFg3QSEQvF2=M1LrcnNCVkeHUh?=
NCI-H510ANX3jN2hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTVeIpoUUN3ME2zPE43PDVzIN88US=>Mm\ZV2FPT0WU
NMC-G1NXfKXWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXMeHRKSzVyPUO4MlczOjJizszNM3fw[HNCVkeHUh?=
SW948Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDOO4FKSzVyPUO4Mlg6PDlizszNNEjhNHdUSU6JRWK=
MFM-223NWXQUXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTqN4k{UUN3ME2zPE46PDNzIN88US=>MX7TRW5ITVJ?
PAN1MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTN6Lkm5NVkh|ryPNVLWbVE2W0GQR1XS
MZ7-melM4r0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTQZpRHUUN3ME2zPU4yOTl7IN88US=>NUPoXoxkW0GQR1XS
COLO-679Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY[5WnlHUUN3ME2zPU46PzB6IN88US=>M2i1VXNCVkeHUh?=
SW872Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTRyLkKwN|Eh|ryPNHu5ZmxUSU6JRWK=
HT-1197NG\SU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom2TWM2OD12MD6yPFY6KM7:TR?=NXLxWYFjW0GQR1XS
ES6Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrFUGhXUUN3ME20NE41PTV{IN88US=>NHPremxUSU6JRWK=
SNU-387Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrQTWM2OD12MD64NlM5KM7:TR?=MonOV2FPT0WU
T47DNInSe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\PTWM2OD12MT6wNVkzKM7:TR?=MnOxV2FPT0WU
G-402MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTRzLkC4NFkh|ryPMXHTRW5ITVJ?
MZ1-PCNUmw[GM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfvenFKSzVyPUSxMlgyKM7:TR?=M33LbnNCVkeHUh?=
SW1417MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWOzSnVOUUN3ME20Nk4{ODNizszNNVz4[|llW0GQR1XS
RERF-LC-MSMkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkn6TWM2OD12Mj61NFg4KM7:TR?=M2nIb3NCVkeHUh?=
SF539NWHWSoRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHMPGJKSzVyPUSyMlU2OjlizszNNHfOTmVUSU6JRWK=
ESS-1M4m3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TvcmlEPTB;NEOuOVU2QCEQvF2=MlTFV2FPT0WU
RO82-W-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\ofGlEPTB;NEOuOlE2OyEQvF2=NYP2SJd6W0GQR1XS
S-117NXvk[oxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[0TWM2OD12Mz62PVU5KM7:TR?=M2nPTXNCVkeHUh?=
SW756MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\aSIt3UUN3ME20N{45OjR{IN88US=>MWLTRW5ITVJ?
CP66-MELMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTR3LkexOFMh|ryPNHLI[FNUSU6JRWK=
H-EMC-SSMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\GTGlEPTB;NEWuO|Y6OyEQvF2=MnPNV2FPT0WU
NCI-H2052M4\KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnrTWM2OD12NT65NFI4KM7:TR?=Mn\RV2FPT0WU
SW684NHTaXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjMNldKSzVyPUS3MlAxQDFizszNM{n6W3NCVkeHUh?=
HCC1569MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPDTWM2OD12Nz6xOlU5KM7:TR?=NVjHfXNKW0GQR1XS
KGNMmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlu0TWM2OD12Nz6zN|EyKM7:TR?=NILUVlNUSU6JRWK=
LCLC-103HMoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljuTWM2OD12Nz60OFA1KM7:TR?=M3fXZXNCVkeHUh?=
SW780MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXwd3NSUUN3ME20O{43OzVzIN88US=>NInXWZVUSU6JRWK=
NCI-H1703NGLPZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\1TWM2OD12OD6zN|UzKM7:TR?=NWS4T|lZW0GQR1XS
HCC1395Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTR6Lke0N|Ih|ryPM4X2THNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02588261 Recruiting Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc.|Astellas Pharma Inc November 2015 Phase 3
NCT02326285 Not yet recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca August 2015 Phase 2|Phase 3
NCT02321293 Recruiting Lung Cancer Lady Davis Institute|Jewish General Hospital August 2015 Phase 1
NCT02447419 Recruiting Solid Tumor Samsung Medical Center July 2015 Phase 2
NCT02484755 Recruiting Cushings Disease|Corticotrophin Adenoma Huashan Hospital June 2015 Phase 2

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90
Formula

C22H24ClFN4O3

CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 12 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation (11)


Click to enlarge
Rating
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Rating
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Rating
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Rating
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Rating
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h
Results

Product Use Citation (85)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us